XORTX Therapeutics Inc (XRTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.92 (+15.66%), Market cap $0.00B, 52-week low–high $0.34 ~ $3.03.
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is ba
Financial statements, price targets, institutional (13F) holdings and related news for XORTX Therapeutics Inc are updated in real time on BlackAll Trade.
XORTX Therapeutics Inc trades at $1.92 (+15.66%). Real-time quotes and charts are available on BlackAll Trade.
XORTX Therapeutics Inc has a market cap of about $0.00B.
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-